Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial

BACKGROUND: Canagliflozin reduced renal and cardiovascular events in people with type 2 diabetes in the CREDENCE trial. We assessed efficacy and safety of canagliflozin by initial estimated glomerular filtration rate (eGFR). METHODS: CREDENCE randomly assigned 4401 participants with an eGFR of 30 to...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Am Soc Nephrol
Главные авторы: Jardine, Meg J., Zhou, Zien, Mahaffey, Kenneth W., Oshima, Megumi, Agarwal, Rajiv, Bakris, George, Bajaj, Harpreet S., Bull, Scott, Cannon, Christopher P., Charytan, David M., de Zeeuw, Dick, Di Tanna, Gian Luca, Greene, Tom, Heerspink, Hiddo J.L., Levin, Adeera, Neal, Bruce, Pollock, Carol, Qiu, Rose, Sun, Tao, Wheeler, David C., Zhang, Hong, Zinman, Bernard, Rosenthal, Norman, Perkovic, Vlado
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Nephrology 2020
Предметы:
Clinical Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7217416/
https://ncbi.nlm.nih.gov/pubmed/32354987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2019111168
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы